Nava Therapeutics has launched with $89 million in funding to advance a lipid nanoparticle platform intended to deliver RNA medicines beyond the liver, with initial programs significantly focused on in vivo CAR-T and kidney-targeted genetic medication.
The Cambridge and Philadelphia-based organization is developing lipid nanoparticles, or LNPs, designed to spread immune cells and kidney tissue rather than defaulting to liver uptake. The financing was backed by a group of investors, including RA Capital Management, Leaps by Bayer, PureTech Health, a large U.S. healthcare-focused fund, and a sovereign wealth fund. Proceeds will support preclinical programs toward clinical trials, increasing Nava's lipid chemistry library, and operations in both sites.
Nava's lead program, NT-001, is an anti-CD19 in vivo CAR-T candidate intended to generate CAR-T cells directly inside the body. Instead of removing a patient's T cells, adapting them at a specific production facility, and reinfusing them weeks later, the strategy uses an LNP to deliver mRNA encoding a humanized CD19 CAR directly to T cells in vivo.
This strategy could simplify the CAR-T management paradigm by eliminating patient-centric ex vivo production, viral vector manufacturing, cold-chain logistics, and lengthy turnaround times. Because the CAR is expressed transiently for days to weeks, the strategies enable repeat or adjustable dosing without permanent genomic incorporation.
A central complexity for LNP-driven medicines is liver tropism. After intravenous administration, major conventional LNPs adsorb serum apolipoproteins like ApoE, which enhances recognition by LDL receptors on hepatocytes and drives liver uptake. Nava's platform uses a new "immunotropic" ionizable lipid intended to lower ApoE adsorption and restrict hepatic biodistribution via lipid chemistry alone.
For NT-001, Nava integrates this passive liver de-targeting strategy with CD8-specific targeting ligands to actively direct the particle toward CD8-positive T cells. The organization describes this as a layered delivery approach in which lipid chemistry addresses organ-driven biodistribution and targeting ligands address cell-type specificity.
The platform builds on SENT-seq, a single-cell LNP screening technology industrialized in the laboratory of James Dahlman at Georgia Tech and Emory University. SENT-seq enables hundreds of barcoded LNP preparations to be screened instantaneously in vivo, measuring biodistribution, practical RNA delivery, and cellular response at single-cell resolution.
According to Towards Healthcare, the LNP manufacturer at commercial scale market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 1.69 billion in 2026 to approximately USD 8.02 billion by 2035, representing a compound annual growth rate (CAGR) of 18.9% from 2026 to 2035, driven by nanoparticles are a multipurpose class of ingredients engineered at the nanoscale, providing unique characteristics that can be precisely tailored for therapeutic applications. Their size, superficial characteristics, and compositions enable targeted interactions with biological technology, creating them suitable carriers for medication delivery. Nanoparticles provide significant benefits as a drug delivery technology, involving enhanced stability, controlled release, and the capability to carry poorly soluble compounds.
In non-human primate research, NT-001 shaped deep B-cell depletion in the spleen and lymph nodes, consistent with on-target CD19 CAR-T activity. PET imaging presents selective splenic and lymph node acceptance with insignificant off-target signal, while liver enzymes remained in the normal range. Cytokine elevations were transient and returned to the starting point within 72 hours.
Beyond T-cell delivery, Nava is developing a kidney-targeted program. The kidney remains a difficult organ for LNP delivery as glomerular filtration and tubular architecture present size and charge barriers. Nava has shown preclinical data on kidney gene editing, suggesting the platform supports the delivery of more challenging RNA payloads such as guide RNA and nuclease-encoding mRNA.
Nava involves a highly competitive in vivo CAR-T sector that has attracted major pharmaceutical investment. Companies pursuing LNP-mRNA or viral delivery strategies are seeking to make CAR-T cells directly in the patients, possibly lessening expenses and increasing access as compared with conventional ex vivo CAR-T production.
Though the sector still lacks public human proof-of-concept data for LNP-mRNA in vivo CAR-T. Nava's next significant milestones involve IND-driving advancement, clinical translation of its liver de-targeting and T-cell targeting outline, and demonstration that its preclinical delivery benefits translate safely and efficiently in persons.
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
A recent report by Towards Healthcare emphasizes that the LNP manufacturer at commercial scale market offers exciting opportunities to improve bioavailability, increase solubility, and enable controlled, site-specific drug delivery. These applications span vaccines, cancer therapies, and gene treatments. Lipid nanoparticle technology, a branch of nanotechnology, is designed to optimize the performance of LNPs in pharmaceutical products. As the most advanced non-viral gene delivery system, lipid nanoparticles effectively transport nucleic acids into cells, overcoming a major challenge in developing genetic medicines. LNPs open new possibilities in genetic medicine, including gene editing, rapid vaccine development, immuno-oncology, and treating rare or hard-to-treat disease areas often limited by inefficient nucleic acid delivery.
